fingolimod hydrochloride has been researched along with fostamatinib in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (fostamatinib) | Trials (fostamatinib) | Recent Studies (post-2010) (fostamatinib) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 156 | 33 | 129 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | fostamatinib (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase SYK | Homo sapiens (human) | 0.142 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, J; Hong, X; Rang, X; Xu, C; Yin, X; Zhou, Y | 1 |
1 other study(ies) available for fingolimod hydrochloride and fostamatinib
| Article | Year |
|---|---|
Immune cells transcriptome-based drug repositioning for multiple sclerosis.
Topics: Drug Repositioning; Fingolimod Hydrochloride; Gene Expression Profiling; Humans; Leukocytes, Mononuclear; Multiple Sclerosis; Phosphatidylinositol 3-Kinases; Transcriptome | 2022 |